Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Prolia for new indications

Sep. 20, 2011

Taisho sodium/glucose cotransporter 2 inhibitor shows promise in patients with type 2 diabetes

Sep. 20, 2011

Preclinical and clinical data on migalastat made available

Sep. 20, 2011

Pronova BioPharma initiates first-in-human study of PRC-4016

Sep. 19, 2011

SMART-5 trial data reported for bazedoxifene/conjugated estrogens

Sep. 19, 2011

Karo Bio obtains clearance for phase III trial in HeFH

Sep. 19, 2011

Vivus reaches agreement with FDA on Qnexa NDA

Sep. 19, 2011

Catabasis Pharmaceuticals identifies new NF-kappa-B activation inhibitors

Sep. 19, 2011

Ono Pharmaceutical secures new Japanese approval for Glactiv

Sep. 19, 2011

Top-line phase I data on VRS-859 for type 2 diabetes

Sep. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...